A 239-query cross-sectional survey was sent out through e-mail in January 2017 to collect extensive info on cannabis use from Canadian healthcare cannabis patients registered with a federally authorized licensed cannabis producer, resulting in 2032 comprehensive surveys.
The survey gathered detailed demographic information and extensive info on patient patterns of healthcare cannabis use, like concerns assessing the self-reported effect of cannabis on the use of prescription drugs, illicit substances, alcohol, and tobacco.
Participants have been 62.six% male (n = 1271) and 91% Caucasian (n = 1839). The imply age was 40 years old, and discomfort and mental wellness situations accounted for 83.7% of all respondents (n = 1700). Then, 74.six% of respondents reported daily cannabis use (n = 1515) and imply quantity employed per day was 1.5 g. The most usually cited substitution was for prescription drugs (69.1%, n = 953), followed by alcohol (44.five%, n = 515), tobacco (31.1%, n = 406), and illicit substances (26.six%, n = 136). Opioid medicines accounted for 35.three% of all prescription drug substitution (n = 610), followed by antidepressants (21.five%, n = 371). Of the 610 mentions of certain opioid medicines, individuals report total cessation of use of 59.three% (n = 362).
This study delivers a distinctive point of view by focusing on the use of a standardized, government-regulated supply of healthcare cannabis by individuals registered in Canada’s federal healthcare cannabis program. The findings present a granular view of patient patterns of healthcare cannabis use, and the subsequent self-reported impacts on the use of opioids, alcohol, and other substances, adding to a increasing physique of academic study suggesting that elevated regulated access to healthcare and recreational cannabis can outcome in a reduction in the use of and subsequent harms related with opioids, alcohol, tobacco, and other substances.